LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive signaling of the RAS-RAF-MEK pathway. Elevated LNK enhances cell growth and survival in adverse conditions. Forced expression of LNK inhibits signaling by interferon-STAT1 and suppresses interferon (IFN) induced cell cycle arrest and cell apoptosis. In contrast, silencing LNK expression by either shRNA or CRISPR-Cas9 potentiates the killing effect of IFN. The IFN-LNK signaling is tightly regulated by a negative feedback mechanism; melanoma cells exposed to IFN upregulate expression of LNK to prevent overactivation of this signaling pathway. Our study reveals an unappreciated function of LNK in melanoma and highlights the critical role of the IFN-STAT1-LNK signaling axis in this potentially devastating disease. LNK may be further explored as a potential therapeutic target for melanoma immunotherapy.
A dvanced stage melanoma is one of the most devastating cancers causing nearly 50,000 annual deaths worldwide 1 . The majority of cutaneous melanomas are driven by oncogenic gain of function mutant BRAF (V600E,~40-50%) 2, 3 , followed by mutant NRAS, RAS inhibitor NF1 (loss of function) and occasionally mutant c-Kit. Melanoma cells generally respond poorly to traditional chemotherapy and radiotherapy, until recently rendering a lack of efficient therapeutic approaches for most of the late stage patients. Development of BRAF inhibitors vemurafenib (PLX4032) [4] [5] [6] and dabrafenib and immune checkpoint blockade antibodies which target either cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1) 7, 8 have dramatically altered the therapeutic landscape of melanoma in the past few years 9, 10 . These approaches, particularly antibodies against immune checkpoint blockade, show strikingly durable responses resulting in significant improvement of overall survival of a subset (30-40%) of patients 8 . Despite these remarkable achievements, resistance to therapy and melanoma recurrence often occurs 11 . Specifically, about 60-80% of the melanoma patients do not response to initial PD-1/CTLA-4 antibody therapy 12, 13 (primary resistance), and 20-30% of the initial responders develop resistance to treatment, with progressive disease 14 . Hence, a better understanding is clearly needed in regards to the signaling pathways governing the survival of melanoma cells in the setting of immunotherapy.
Recently, two studies noted the crucial role of the interferon (IFN) pathway in melanoma patients who become resistant to either PD-1 or CTLA-4 antibody therapy 15, 16 . Loss of function mutations of JAK1/2 were found in patients with recurrent melanoma who initially responded to PD-1 antibody, or in the primary nonresponder (patients who never responded to the therapy) 17 . Functional studies undertaken by the same researchers suggested that loss of JAK2 function in melanoma cells could impairs IFN signaling, causing resistance to T cell-mediated cytotoxicity and thereby leading to recurrence of the melanoma 15, 17 . Similar conclusions have been reached using in vivo CRISPR-Cas9 library screening studies showing that sgRNAs targeting Jak1/Jak2 and Stat1 as well as interferon receptors were significantly enriched in murine melanoma B16 cells placed in immune-competent, syngeneic C57B/L mice, compared to the same cells (with the same sgRNA library pool) grafted in immunodeficient mice 18, 19 . These studies underscore the crucial role of IFN-JAK/STAT1 signaling in the immune escape of melanoma cells, consistent with dysregulation of the JAK-STAT signaling pathway facilitating progression of melanoma. Loss of the JAK-STAT signaling provides a selective growth/survival advantage for melanoma cells to thwart immune surveillance allowing negative modulators of this signaling to be explored as a potential therapeutic target.
LNK (SH2B3) is a key negative regulator of JAK-STAT signaling, which has been extensively studied in malignant hematopoietic diseases [20] [21] [22] [23] . As an adaptor protein, LNK recognizes and binds to activated, phosphorylated tyrosine proteins through its SH2 domain, resulting in the inhibition of these activated kinases. Within this context, LNK is a potent tumor suppressor in hematopoietic malignancies 22, 24, 25 , as many hematopoietic cancers are mainly driven by gain of function receptor tyrosine kinase (RTK) 24 . For example, in myeloid proliferative disorder (MPD), a blood cancer which frequently (~90-95%) harbors the V617F gain of function mutant JAK2 26 , LNK behaves as an antiproliferative effector by directly binding and suppressing the signaling of this mutant kinase 20, 27 . Indeed, loss of function mutations of LNK occur in MPD patients (particularly those with wild-type JAK2) 27, 28 and occasionally in Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) 29 . Most LNK studies have focused on its role in hematopoietic disease, often using murine Lnk knockout models [23] [24] [25] [30] [31] [32] . Although LNK is widely expressed in a variety of cancer cells (Fig. 1a) , its function in solid tumors has not been fully explored. In this study, we find that LNK is highly expressed in melanoma, and aberrant elevation of LNK confers a selective survival advantage for melanoma cells against the anti-proliferative and pro-apoptotic effect of interferon. Our study identify LNK as a critical regulator of the IFN-STAT1 pathway; and aberrantly expressed LNK probably contributes to immune evasion and tumorigenesis of melanoma. 33 , which are known to express considerable level of LNK, we began our analysis with cancer cell line data because they lack infiltrating lymphocytes and stroma cells. Among the 881 different cancer cell lines in the CCLE database and 317 cancer cell lines in the CellLineNavigator database (E-MTAB-37, Transcriptomics for Cancer Cell Line Project), LNK mRNA is significantly upregulated in cutaneous (skin) melanomas (Fig. 1a , upper and middle panels). Consistently, among the >8000 RNA sequencing data from primay cancer samples in The Cancer Genome Atlas (TCGA), melanoma samples expressed the highest LNK mRNA (Fig. 1a, lower panel) . Compared to either normal skin tissue ( Supplementary Fig. 1 , RNA sequencing of 473 sun-exposed normal skin samples and 387 non-sunexposed normal skin samples, collected from the GTEX database [https://www.gtexportal.org]) or benign nevi, LNK mRNA was significantly upregulated in the melanoma samples, particularly in advanced stages of the disease (vertical growth phase, metastatic growth phase vs primary/in situ melanoma, Fig. 1b-d ) and ranked as one of the top 1% overexpressed genes in melanoma (Riker Melanoma, Oncomine database, Fig. 1b ). We performed western blot and immunohistochemistry (IHC) staining to confirm the elevated expression of LNK protein in melanoma. In melanoma tissue arrays (ME242a, obtained from Biomax Inc), all of the melanoma section cores (n = 12) were heavily stained with the LNK antibody (Fig. 1e) , while considerable less staining was found in normal skin tissue. We further extended the IHC study to a large melanoma patient cohort (tissue arrays established at Melanoma Institute Australia, The University of Sydney, Australia) including 163 melanoma patient samples. Strong staining of LNK was observed (score = 3 or 2) in the majority of the melanoma samples (81%). In addition, when we separated the stage 3 patients (which contained the largest patient number with similar stage of disease for analysis) based on the LNK staining results, a trend toward inferior overall survival was found in patients with high LNK protein expression in their tumors ( Supplementary Fig. 2 ).
Results

LNK
LNK expression is correlated with RAS-RAF signaling. We sought to examine the underlying mechanism governing the aberrant elevation of LNK in melanoma. First, we analyzed the CCLE melanoma cell lines to assess whether any potential correlation occured between LNK and other oncogenic abnormalities. We separated the melanoma cell lines based on their driver mutation (BRAF V600E, NRAS Q61K/L, c-KIT or other), and found that LNK expression was significantly higher in cell lines that harbored BRAF and NRAS mutations (Fig. 1f) , suggesting that hyperactivated RAS-RAF-MEK signaling may correlate with LNK expression in melanoma. To pursue this hypothesis, we queried the LNK mRNA expression and performed a metaanalysis of cDNA microarray data in the GEO database. LNK mRNA expression was significantly affected by perturbation of the MAPK signaling in melanoma cells. Inhibition of mutant BRAF (V600E) activity by either the BRAF inhibitor Vemurafenib (PLX4032, Supplementary Fig. 3a) or BRAF siRNA markedly reduced the LNK transcript levels in melanoma A375 cells ( Supplementary Fig. 3b ), while forced expression of an activated BRAF (V600E) generated the opposite effect (~four-fold increased LNK, Supplementary Fig. 3c ). Similarly, silencing expression of mutant NRAS Q61K expression in a doxycyclineinducible murine melanoma model reduced LNK mRNA (GSE39984) (Supplementary Fig. 3d ). In contrast, forced expression of either activated NRAS Q61K or HRAS/KRAS G12V in the immortalized melanocyte cell line Mel-ST significantly increased LNK transcripts (GSE62827, Supplementary Fig. 3e ). Suppressing the MAPK kinase activity in melanoma cells with a MEK inhibitor (U0126) consistently downregulated LNK expression ( Supplementary Figs. 3b, d ). We performed RT-PCR and western blot to validate our in silico observations. In three melanoma cell lines that harbored the BRAF V600E mutation (A375, M229 and M238), treatment of the cells (24 h) with either the BRAF inhibitor vemurafenib (PLX4032) or a MEK inhibitor (U0126) significantly downregulated the LNK mRNA and protein expression (Fig. 1g, h ). Collectively, these data suggest that aberrant expression of LNK is correlated with the hyperactivated RAF/MAPK signaling in melanoma.
LNK promotes growth and survival of melanoma cells. To evaluate the biological relevance of elevated LNK in melanoma cells, we first examined the effect of LNK silencing in melanoma cells using the database of Novartis DRIVE cancer cell lines [https://oncologynibr.shinyapps.io/drive/]. In this large-scale (398 different cancer cell lines) shRNA library screening project, cells were infected with shRNA library pool targeting 7837 genes (each gene was targeted by~20 different shRNAs) 34 . The lentiviral shRNA infected cells were allowed to grow for 14 days after infection. The presence of each shRNA was analyzed by highthroughput-sequencing. Enrichment of shRNA at day 14 compared to day 0 indicated that it targeted an anti-growth gene, while depletion of a shRNA suggested it targeted a pro-growth gene (e.g., shRNAs targeting BRAF in melanoma, Supplementary  Fig. 4 ). In 27 of the 35 melanoma cell lines examined, LNK shRNA (ATARiS value) was consistently decreased at day 14 (compared with day 0), suggesting that silencing LNK by shRNA retards cell growth of most melanoma cell lines (Fig. 2a) .
We generated a number of melanoma cell lines that stabilized either over-expressed (OE) or silenced LNK (either by shRNA or CRISPR-Cas9). Lentivirus-transduced melanoma cells were selected using puromycin, and either forced-expression or silencing of LNK were confirmed by western blot. By MTT assay, silencing LNK modestly retarded growth of melanoma cell lines, while forced expression of LNK showed either no significant difference (A375, Supplementary Fig. 5 ) or modestly reduced cell growth (M202). However, forced expression of LNK enhanced the anchorage-independent clonal growth in soft agar (Fig. 2b ) and generated bigger tumors in an in vivo xenograft model (Fig. 2c, d) ; while silencing of Lnk using CRISPR-Cas9 reduced the tumor formation of murine melanoma B16/F10 cells (Fig. 2c,  d ). These data suggest that LNK modestly enhances tumorigenesis and the self-renewal potential of melanoma cells.
In addtion, LNK enhances cell survival in various adverse conditions. Melanoma cells with enforced expression of LNK showed increased resistance to anokisis (induced by cell growth in ultra-low attachment surfaces resulting in cells detaching from their surrounding extracellular matrix) (Fig. 2e, f) . Indeed, western blot analysis of these cells showed a reduction of expression of both major apoptotic markers (cleavage caspase 3/9, cleavage PARP) and pro-apoptotic BH3 protein BIM ( LNK inhibits signaling of IFN-STAT1. Recent studies suggest that the IFN-JAK1/2-STAT1 pathway plays a central role in T cellmediated killing of tumor cells; and perturbation of this pathway leads to resistance of immune check point blockade in melanoma 15, 16 . IFN released by CD8+ T cells binds to the IFN receptors of tumor cells, stimulating expression of a number of IFN responsive genes signaling through JAK-STAT1 pathway. LNK is a well-characterized JAK-STAT suppressor in hematologic malignancies 20, 21 , prompting us to test whether the prominently expressed LNK in melanoma cells was involved in regulation of the IFN pathway. Melanoma cells exposed to recombinant IFN protein [either type I (alpha, beta) or type II (gamma)] quickly activated the interferon signaling pathway, as evidenced by heavy phosphorylation of STAT1 as early as 30 min following IFN treatment (Fig. 3a,  b) . Activated STAT1 migrated into the nucleus initiating transcription of downstream interferon regulatory/responsive genes. Forced expression of LNK profoundly suppressed the IFN (either alpha, beta or gamma) induced phosphorylation of STAT1 (Fig. 3) , while silencing of LNK using either shRNA or CRISPR-Cas9, generated the opposite effect. Consistently, the major downstream markers of IFN signaling, IRF1 and PD-L1, were downregulated in the LNK overexpressed cells, while higher levels of these proteins were detected in the LNK silenced cells. To preclude the possibility that fetal bovine serum (contains different cytokines/growth factors and may affect LNK expression and downstream signaling) affects our analysis, experiments were performed either with or without serum using several cell lines. Results were consistent with LNK regulating IFN-JAK-STAT in both culture conditions.
We performed immunoprecipitation (IP) to examine the protein interaction between LNK and other proteins. Melanoma cells were treated with IFN gamma for 30 min, lysed and LNK protein was pulled-down using LNK antibody (Santa Cruz (A-12): sc-393709). Western blot analysis showed that STAT1 was pulled down together with LNK protein (Fig. 3e) . Similarly, reciprocal immunoprecipitation using STAT1 antibody (Cell Signaling, 9172S) showed LNK was co-precipitated with STAT1 protein. We performed GST-pull down experiments to examine Fig. 1 LNK expression is elevated in melanoma and associated with RAS-RAF-MEK signaling. a LNK mRNA expression is elevated in melanoma cell lines and primary melanoma samples. Upper panel, LNK expression in 877 cancer cell lines (data extracted from microarray data of CCLE). Middle panel, LNK expression levels in 332 cancer cell lines (data extracted from microarray data of E-MTAB-37). Lower panel, LNK expression in primary cancer samples (data retrieved from TCGA RNA sequencing data using Cbio cancer portal). b LNK expression is elevated in melanoma, compared with normal skin tissue (data obtained from Oncomine database). Mean ± (+ & −) SD, ****p < 0.0001, unpaired t-test. c LNK expression is upregulated in advanced melanoma (metastasis) compared with primary melanoma. Mean ± SD, ****p < 0.0001, unpaired t-test. d LNK expression is upregulated in advanced stages of melanoma (vertical growth phase, metastatic growth phase, etc.) compared with either in situ melanoma or benign nevus. e IHC staining of melanoma tissue array. LNK is heavily stained in all of the melanoma tissue cores (n = 12), while significantly weaker staining was detected in normal skin controls (skin, n = 12). Scale bar = 200 µm (left panel) or 20 µm (right panel). f Melanoma cell lines in CCLE were classified into different groups based on their oncogenic drivers (BRAF V600E, NRAS Q61K/L, HRAS, c-KIT and other drivers). LNK expression levels were significantly elevated in cell lines driven by mutant BRAF V600E and NRAS Q61K. *p < 0.05; ***p < 0.001; unpaired t-test. g, h Inhibitor of BRAF [Vemurafenib (PLX4032)] or MEK (U0126) consistently downregulated LNK expression in three melanoma cell lines carrying the BRAF V600E mutation. Real time PCR was performed 24 h after exposure to the inhibitors (g, mean + SD, n = 3). Western blot was performed 48 h after the treatment (h). *p < 0.05; **p < 0.01; unpaired t-test. Error bars represent SD. All p values were calculated using two tailed t-test whether a direct interaction occur between LNK and STAT1 protein. Recombinant GST fusion protein of LNK (PH or SH2 domain) and STAT1 were generated and purified using E.coli strain TXK1 (Stratagene). The recombinant proteins were incubated with the cell lysate of HEK293T cells transfected with Flag tag STAT1 expressing constructs (GST-LNK pull down experiment) or cell lysis of A375 expressing V5-LNK (GST-STAT1 pull down experiment). Both PH and SH2 domain of LNK, but not the GST control protein, can bind to the STAT1 protein and they were pulled down together as a protein complex (Fig. 3f, g WM88  UACC62  C32  K029AX  A101D  A2058  WM1799  RPMI7951  SH4  WM793  HS294T  WM115  HS939T  HS944T  SKMEL5  UACC257  IGR37  IGR1  MELHO  HS852T  COLO679  IGR39  LOXIMVI  COLO829  SKMEL3  WM2664  SKMEL2  IPC298  RVH421  SKMEL28  COLO741  A375  SKMEL30  MEWO Fig. 6 )]. Conversely, silencing of LNK significantly enhanced expression of interferon-inducible genes (Fig. 5, Supplementary  Fig. 7) . Analysis of the RNA sequencing data using Gene Set Enrichment Analysis (GSEA) of cells silencing LNK showed a remarkable enrichment of the expression signatures of interferon (False Discovery Rate (FDR) q-values = 0), graft versus host disease, allograft rejection, immune effector process and antigen processing pathway (Fig. 5a ). An inverse correlation (negative enrichment) of MYC targets and telomeres signature, as well as melanoma relapse gene expression signature were also observed (signature enriched in control cells, Supplementary Fig. 8 ). Depletion of Myc expression has recently been shown to reverse the immune evasion of lung cancer cells 35 . Notably, expression of a number of HLA genes was suppressed by LNK. For example, a series of MHC class I and II genes, including HLA-DMA, HLA-DOB, etc, were downregulated in the LNK overexpressing A375 cells (Figs. 4b, 5b ) and significantly upregulated in the same cell line silenced with LNK using CRISPR-Cas9 guide RNA. Hence, prominent expression of LNK down-regulates the IFN-induced MHC gene expression, probably leading to a decreased MHCmediated antigen presentation and potentially reducing T cell recognition.
Recombinant IFN alpha has been used as an adjuvant therapeutic reagent for resected, advanced stage melanoma; 36 and IFN can directly suppress proliferation of melanoma cells and induce their apoptosis 37 . Indeed, melanoma cells treated with interferon gamma have markedly suppressed growth (Fig. 6a) . Overexpression of LNK attenuates this effect and confers a selective growth/survival advantage (Fig. 6a, b , MTT and foci formation assays). In contrast, silencing of LNK by either shRNA or CRISPR-Cas9 potentiates the effect of interferon, reducing cell proliferation and formation of foci. Interferon gamma-induced rapid apoptosis, reflected by caspasemediated cleavage of Poly (ADP-ribose) polymerase (PARP) after IFN exposure. Forced expression of LNK potently inhibited cleavage of PARP and suppressed IFN induced apoptosis (Fig. 3a,  d ). The A375 cell line is resistant to interferon induced apoptosis 38 , and cleavage of PARP was hardly detectable, but a marked retardation of cell growth was observed upon IFN-γ treatment. The anti-proliferative effect of IFN in this cell line was probably due to the suppression of cell cycle progression; and as suggested from our RNA sequencing data, LNK probably reversed this effect through upregulation of cell cycle pathway genes (Fig. 4a) .
Based on the above observations, we hypothesized that a higher level of LNK expression will suppress the interferon pathway and confer a selective survival advantage to melanoma cells; therefore, those patients who have higher levels of LNK expressed in their tumor cells will be less likely to respond to PD-1 antibody therapy. We examined the LNK mRNA expression using RNA sequencing data of a cohort of melanoma patients who were uniformly treated with PD-1 antibody (data retrieved from GSE78220) 39 . RNA was extracted from melanoma biopsy samples before treatment. A trend towards higher levels of LNK mRNA was found in non-responding patients [responding cohort (n = 15), FPKM mean value = 15.89; non-responding cohort (n = 13) = 32.43], although the difference did not reach statistical significance (p = 0.13, unpaired t-test) (Fig. 6c) . In contrast, the mRNA level of the other two SH2B family members (SH2B1 and SH2B2) showed no difference in expression between the responding and non-responding patients (Supplementary Fig. 9 ). To test further this hypothesis, murine melanoma cells (B16/F10 or D4M.3A) with silenced Lnk were injected into syngeneic C57BL/6 mice, and the mice were treated with anti-mouse PD-1 antibody (Fig. 6d-f, Supplementary Fig. 10 ). Silencing Lnk by CRISPR-Cas9 enhanced the tumor-suppressive effect of PD-1 antibody retarding tumor growth, supporting the concept of further exploring the therapeutic potential of targeting LNK plus immune checkpoint therapy. Mean + SEM. *p < 0.05; ***p < 0.001; unpaired t-test. e, f Force expression of LNK (LNK OE) enhances cell survival and confers resistance to anoikis related cell death (induced when cells are grown anchorage-free). *p < 0.05, unpaired t-test. f Representative result of Annexin V staining after melanoma cells was grown on ultra-low binding plates. GFP, overexpression GFP control; LNK, overexpression of LNK. g Overexpression of LNK attenuates anoikis cell death. Cells were grown on ultra-low attachment plates for 48 h to induce anoikis before protein extraction. The western blot showed that overexpression of LNK reduced expression of apoptosis markers. Ctrl, control cells; LNK, cells overexpressing LNK. h LNK enhances cells survival in adverse conditions: M368 melanoma cells were grown either in nutrition deprived media (100% PBS or 1:10 diluted DMEM media, diluted with isotonic PBS) or exposed to transcription inhibitor actinomycin-D (mean + SD, n = 3). **p < 0.05, unpaired t-test. Error bars represent either SEM (d) or SD (b, e, and h). All p values were calculated using two tailed t-test IFN-STAT1 induces LNK expression as a negative feedback. Melanoma cells treated with IFN-γ upregulated LNK expression (Fig. 6g) . Analysis of the ChIP-seq data from the ENCODE database [https://www.encodeproject.org/] reveals strong IRF-1 enrichment at the transcriptional start site of LNK associated with IFN-γ treatment (Fig. 6h, 6 h), suggesting that activated IFN-STAT1 signaling turns on the transcription factor IRF-1 to activate the transcription of LNK. This upregulation may act as a negative feedback mechanism to prevent over-activation of the pathway and fine tune the magnitude and duration of signaling of IFN. Melanoma cells may also use this signaling axis to ameliorate the anti-proliferative effect of IFN.
Discussion
Melanoma harbors the highest mutational burden among cancers 40 and is frequently infiltrated with T lymphocytes 41 . Their high mutational load increases the likelihood of tumor specific 47 . Among these escape mechanisms, IFN signaling plays a central role in coordinating T cell activity and killing cancer cells. In a murine model of melanoma, blockade of Ifna signaling using an anti-Ifnar antibody completely abolish tumor rejection mediated by Pd-1 antibody therapy 48 . IFN released by CD8+ T cells activates the JAK-STAT1 signaling pathway; upon activation, the IFN receptor recruits JAK1/2 tyrosine kinase to phosphorylate the major downstream effector STAT1. The latter translocates into the nucleus to stimulate transcription of INFstimulated response genes. We identified LNK as a negative regulator of the signaling by JAK-STAT in melanoma. Elevated LNK protein in these melanoma cells confers selective survival advantage by suppressing signaling by IFN. The elevated LNK is associated with the mutant hyper-activated RAS-RAF signaling pathway in melanoma cells. Hence, a potential therapeutic rationale for the combination of a RAF/MEK inhibitor (downregulate LNK expression) with an immune checkpoint blockade antibody 49, 50 .
The observation that LNK suppresses the IFN-induced MHC class II and I genes is of interest. The MHC complex mediates antigen cell surface presentation and plays a central role in neoantigen-mediated T cell recognition 51 . Recently, Johnson et al found that MHC-II gene expression was correlated with response to PD-1/PD-L1 antibody therapy 52 and the expression of HLA-DR correlated with pro-immune/inflammatory gene signature 52 .
Response to PD-1 antibody therapy was associated with preexisting IFN-γ signaling including the display of MHC class II proteins on untreated melanoma patient samples 53 . Overexpression of LNK suppresses expression of MHC genes, leading to a reduction of cellular antigenicity, helping the tumor cells evade immune surveillance. Indeed, a negative correlation of LNK and MHC gene expression was observed in melanoma samples ( Supplementary Fig. 11) . Notably, recent genome-wide association studies (GWAS) identified a single nucleotide polymorphism (SNP) in the LNK coding region which is significantly associated with a variety of autoimmune diseases [e.g., celiac disease 54 , autoimmune hepatitis type 1 55 ]. LNK may suppress proinflammatory cytokines induced by autoantigen presentation through down-regulation of MHC/HLA genes in these diseases, and this deserves further study.
The clinical translation of targeting LNK in melanoma patients may have the potential to improve the effect of immune checkpoint therapy and increase patient survival. Pharmacologic targeting LNK using small molecule, if feasible, not only may enhance the tumor immunity in cancer cells, but may also enhance the activity and cell proliferation of tumor infiltrating T cells. Silencing LNK using small molecules may also enhance the JAK-STAT signaling in lymphocytes enhancing their proliferation and activation. Targeting LNK's downstream phosphatase may represent an alternative approach to enhance the JAK-STAT signaling and tumor immunity in cancer cells 18 . We are currently performing mass spectrometry experiments to identify this phosphatase.
In summary, we showed that expression of the adaptor protein LNK is significantly elevated in melanoma cells, and enhanced transcription of LNK is associated with the signaling of the hyperactivated RAS-RAF-MEK pathway (Fig. 6i) . Ectopic expression of LNK enhances cell survival and tumor growth and suppresses IFN-induced apoptosis/cell cycle arrest. Our study uncovered an unappreciated function of LNK in melanoma and underscores the important role of IFN-STAT1-LNK signaling in this potentially devastating disease.
Methods
Study design. For the murine xenograft experiment, a sample size of n ≥ 6 per group was used to achieve a statistical significance of p < 0.05. All tumor samples were included in the analysis. Experiments were performed in a non-blinded way.
Statistical analysis. GraphPad Prism 6 was used for the statistical analysis. Data were analyzed using unpaired two-tailed t test and presented as means ± SD, unless otherwise indicated. P < 0.05 was considered to be statistically significant.
Cell lines. Melanoma cell line A375 and B16/F10 were from ATCC; primary human melanoma cells (M202, M229, M238, M285, M368) were kindly provided by Dr Antoni Ribas, UCLA. Murine melanoma cell line D4M.3A was provided by Dr David W.Mullins. Cells were maintained in DMEM medium with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin. HEK293T cells were cultured in DMEM medium with 10% FBS.
Reagents. Recombinant human Interferon alpha 1 (CYT-291), Beta 1a (CYT-236), Beta 1b (CYT-234) Gamma (IFN-γ, CYT-206) were obtained from Prospecbio.
Immnuohistochemical (IHC) staining. Melanoma tissue array (ME242a, obtained from US Biomax Inc.) was stained with LNK antibody (R&D, AF5888, the specificity and titration of the antibody for IHC experiment was tested with positive and negative controls 56 ). Staining of tissue arrays of 163 melanoma patient samples was performed at Melanoma Institute Australia, Sydney, Australia. Fig. 3 LNK suppresses signaling of the IFN-STAT Real time qRT-PCR. Total RNA was extracted from cells using RNeasy Mini Kit (QIAGEN). LNK mRNA expression was determined by real time PCR using primer DLW13 CACTTTCCCTCGGTCGTG and DLW 14 GGGACAGCCAGAA-GAACTAA (targeting exons 7 and 8 including the intervening intron of human LNK gene). Primers of IFN induced genes are listed in Supplementary Table 3 . β-Actin or GAPDH were used for normalization.
Lentivirus and generation of stable cell lines. Lentiviral CMV-GFP plasmid SHC003 was obtained from Sigma-Aldrich. Lentivirus construct to express LNK was generated by replacing the GFP with LNK coding region 56 . For gene silencing, shRNA plasmids targeted to LNK [TRCN0000265715 (shRNA15), TRCN0000265716 (shRNA16), TRCN0000256095 (shRNA95) and Non-targeting shRNA SHC002 were obtained from Sigma-Aldrich. CRISPR-Cas9 sgRNAs were RNA sequencing and microarray analysis. mRNA expression was profiled using either high-through-put RNA sequencing or Illumina Human HT-12 v4 Expression BeadChip. Real-time RT-PCR was performed to validate the significantly altered genes.
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The RNA sequencing and microarray data has been deposited in the GEO database under the accession code GSE127764, GSE127333 and GSE127965. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request. A reporting summary for this article is available as a Supplementary Information file.
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